The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
Open accessAbstract
BACKGROUND: Effective new therapies are needed for rheumatoid arthritis. Current therapies target the products of activated macrophages; however, T cells also have an important role in rheumatoid arthritis. A fusion protein--cytotoxic T-lymphocyte-associated antigen 4-IgG1 (CTLA4Ig)--is the first in a new class of drugs known as costimulation blockers being evaluated for the treatment of rheumatoid arthritis. CTLA4Ig binds to CD80 and CD86 on antigen-presenting cells, blocking the engagement of CD28 on T cells and preventing T-cell activation. A preliminary study showed that CTLA4Ig may be effective for the treatment of rheumatoid arthritis. METHODS: We randomly assigned patients with active rheumatoid arthritis despite methotrexate therapy to receive 2 mg of CTLA4Ig per kilogram of body weight (105 patients), 10 mg of CTLA4Ig per kilogram (115 patients), or placebo (119 patients) for six months. All patients also received methotrexate therapy during the study. The clinical response was assessed at six months with use of the criteria of the American College of Rheumatology (ACR), which define the response according to its extent: 20 percent (ACR 20), 50 percent (ACR 50), or 70 percent (ACR 70). Additional end points included measures of the health-related quality of life. RESULTS: Patients treated with 10 mg of CTLA4Ig per kilogram were more likely to have an ACR 20 than were patients who received placebo (60 percent vs. 35 percent, P<0.001). Significantly higher rates of ACR 50 and ACR 70 responses were seen in both CTLA4Ig groups than in the placebo group. The group given 10 mg of CTLA4Ig per kilogram had clinically meaningful and statistically significant improvements in all eight subscales of the Medical Outcomes 36-Item Short-Form General Health Survey. CTLA4Ig was well tolerated, with an overall safety profile similar to that of placebo. CONCLUSIONS: In patients with active rheumatoid arthritis who were receiving methotrexate, treatment with CTLA4Ig significantly improved the signs and symptoms of rheumatoid arthritis and the health-related quality of life. CTLA4Ig is a promising new therapy for rheumatoid arthritis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
(1994) · Medical Entomology and Zoology · Cited by 4,156
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Lipsky, P. E., van der Heijde, D. M. F. M., St. Clair, E. W., Furst, D. E., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Weisman, M., Emery, P., Feldmann, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432202 · Cited by 2,996
Self-citationGregersen, P. K., Silver, J., & Winchester, R. J. (1987) · Arthritis & Rheumatism · doi:10.1002/art.1780301102 · Cited by 2,599
Maini, R., St Clair, E. W., Breedveld, F., Furst, D., Kalden, J., Weisman, M., Smolen, J., Emery, P., Harriman, G., Feldmann, M., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(99)05246-0 · Cited by 2,345
Self-citationA Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis
Bathon, J. M., Martin, R. W., Fleischmann, R. M., Tesser, J. R., Schiff, M. H., Keystone, E. C., Genovese, M. C., Wasko, M. C., Moreland, L. W., Weaver, A. L., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011303432201 · Cited by 1,730
Self-citationMaini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., Tindall, E. A., Fleischmann, R. M., Weaver, A. L., Ettlinger, R. E., Cohen, S., Koopman, W. J., Mohler, K., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707173370301 · Cited by 1,622
Self-citationMueller, D. L., Jenkins, M. K., & Schwartz, R. H. (1989) · Annual Review of Immunology · doi:10.1146/annurev.iy.07.040189.002305 · Cited by 1,493
On closed testing procedures with special reference to ordered analysis of variance
MARCUS, R., ERIC, P., & GABRIEL, K. R. (1976) · Biometrika · doi:10.1093/biomet/63.3.655 · Cited by 1,423
Etanercept Therapy in Rheumatoid Arthritis: A Randomized, Controlled Trial
Moreland, L. W., Schiff, M. H., Baumgartner, S. W., Tindall, E. A., Fleischmann, R. M., Bulpitt, K. J., Weaver, A. L., Keystone, E. C., Furst, D. E., Mease, P. J., et al. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00004 · Cited by 1,379
Self-citationAssociation of the B-Cell Alloantigen DRw4 with Rheumatoid Arthritis
Stastny, P. (1978) · New England Journal of Medicine · doi:10.1056/nejm197804202981602 · Cited by 1,163
CTLA-4–Ig regulates tryptophan catabolism in vivo
Grohmann, U., Orabona, C., Fallarino, F., Vacca, C., Calcinaro, F., Falorni, A., Candeloro, P., Belladonna, M. L., Bianchi, R., Fioretti, M. C., et al. (2002) · Nature Immunology · doi:10.1038/ni846 · Cited by 1,161
INFLIXIMAB AND METHOTREXATE IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Ipsky, P. E. E. L., Illiam, E. W., Urst, D. A. E. F., Reedveld, C. B., Oachim, J., Alden, R. K., Osef, J., Molen, S. S., Eisman, M. I. W., Mery, P. A. E., et al. (2000) · Cited by 1,155
Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., & Ledbetter, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.721 · Cited by 1,127
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Self-citationLinsley, P. S., Greene, J. L., Brady, W., Bajorath, J., Ledbetter, J. A., & Peach, R. (1994) · Immunity · doi:10.1016/s1074-7613(94)80021-9 · Cited by 980
Samsa, G., Edelman, D., Rothman, M. L., Williams, G. R., Lipscomb, J., & Matchar, D. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915020-00003 · Cited by 903
Self-citationHochberg, M. C., Chang, R. W., Dwosh, I., Lindsey, S., Pincus, T., & Wolfe, F. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350502 · Cited by 879
Treatment of Murine Lupus with CTLA4Ig
Finck, B. K., Linsley, P. S., & Wofsy, D. (1994) · Science · doi:10.1126/science.7520604 · Cited by 668
Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?
Mellor, A. L., & Munn, D. H. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01520-0 · Cited by 648
Immunobiology of Tissue Transplantation: A Return to the Passenger Leukocyte Concept
Laffery, K. J., Prowse, S. J., Simeonovic, C. J., & Warren, H. S. (1983) · Annual Review of Immunology · doi:10.1146/annurev.iy.01.040183.001043 · Cited by 509
Lin, H., Bolling, S. F., Linsley, P. S., Wei, R. Q., Gordon, D., Thompson, C. B., & Turka, L. A. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.5.1801 · Cited by 485
Felson, D. T., Anderson, J. J., & Meenan, R. F. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780331001 · Cited by 470
The clinical features of rheumatoid arthritis
Grassi, W., De Angelis, R., Lamanna, G., & Cervini, C. (1998) · European Journal of Radiology · doi:10.1016/s0720-048x(98)00038-2 · Cited by 389
Predominantly T-Cell Infiltrate in Rheumatoid Synovial Membranes
van Boxel, J. A., & Paget, S. A. (1975) · New England Journal of Medicine · doi:10.1056/nejm197509112931101 · Cited by 386
Moreland, L. W., Alten, R., Van Den Bosch, F., Appelboom, T., Leon, M., Emery, P., Cohen, S., Luggen, M., Shergy, W., Nuamah, I., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10294 · Cited by 383
Self-citationThe CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells.
Koulova, L., Clark, E. A., Shu, G., & Dupont, B. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.759 · Cited by 321
Young, J. W., Koulova, L., Soergel, S. A., Clark, E. A., Steinman, R. M., & Dupont, B. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115840 · Cited by 265
Peach, R. J., Bajorath, J., Brady, W., Leytze, G., Greene, J., Naemura, J., & Linsley, P. S. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.6.2049 · Cited by 248
Cush, J. J., & Lipsky, P. E. (1988) · Arthritis & Rheumatism · doi:10.1002/art.1780311003 · Cited by 244
Greene, J. L., Leytze, G. M., Emswiler, J., Peach, R., Bajorath, J., Cosand, W., & Linsley, P. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.43.26762 · Cited by 241
Webb, L. M. C., Walmsley, M. J., & Feldmann, M. (1996) · European Journal of Immunology · doi:10.1002/eji.1830261008 · Cited by 239
The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium
Liu, M. F., Kohsaka, H., Sakurai, H., Azuma, M., Okumura, K., Saito, I., & Miyasaka, N. (1996) · Arthritis & Rheumatism · doi:10.1002/art.1780390115 · Cited by 69
Ranheim, E. A., & Kipps, T. J. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780371113 · Cited by 63
Balsa, A., Dixey, J., Sansom, D. M., Maddison, P. J., & Hall, N. D. (1996) · Rheumatology · doi:10.1093/rheumatology/35.1.33 · Cited by 42
New Approaches to the Therapy of Autoimmune Diseases: Rheumatoid Arthritis As a Paradigm
Moreland, L. W., Heck, L. W., Sullivan, W., Pratt, P. W., & Koopman, W. J. (1993) · The American Journal of the Medical Sciences · doi:10.1097/00000441-199301000-00008 · Cited by 12
Self-citation
Cited by
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition
Genovese, M. C., Becker, J.-C., Schiff, M., Luggen, M., Sherrer, Y., Kremer, J., Birbara, C., Box, J., Natarajan, K., Nuamah, I., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050524 · Cited by 1,241
Self-citationCTLA-4: a moving target in immunotherapy
Rowshanravan, B., Halliday, N., & Sansom, D. M. (2018) · Blood · doi:10.1182/blood-2017-06-741033 · Cited by 1,233
Metadata
- Authors
- Kremer, J. M., Westhovens, R., Leon, M., Di Giorgio, E., Alten, R., Steinfeld, S., Russell, A., Dougados, M., Emery, P., Nuamah, I. F., Williams, G. R., Becker, J.-C., Hagerty, D. T., & Moreland, L. W.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-11-13
- Volume
- 349
- Issue
- 20
- Pages
- 1907-1915
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014081699
- Cited by
- 1,058
- References
- 38
- FWCI
- 53.49
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.